Sign up to save your podcasts
Or
Share Chemo/Immunotherapy Data Increasingly Compelling with Additional Follow-Up (BMIC-009)
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Chemo/Immunotherapy Data Increasingly Compelling with Additional Follow-Up (BMIC-009)
Dr. Jack West assesses the merits of a combination of chemotherapy with pembrolizumab (Keytruda) based on the evolving efficacy data, especially the maturing results for overall survival, with longer follow-up of the KEYNOTE-021g trial.
View all episodes
By H. Jack West, MDDr. Jack West assesses the merits of a combination of chemotherapy with pembrolizumab (Keytruda) based on the evolving efficacy data, especially the maturing results for overall survival, with longer follow-up of the KEYNOTE-021g trial.